Vaccines for visceral leishmaniasis: A review

Journal of Immunological Methods

Volumn 422, Issue , 2015, Pages 1-12

  Jain, Keerti ^a   Jain, N K ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Antigen; Immune response; Protein; Vaccine; Visceral leishmaniasis

Indexed keywords

LEISHMANIA VACCINE; PLASMID DNA; RECOMBINANT PROTEIN; DNA VACCINE; LIVE VACCINE; PARASITE ANTIGEN; PROTOZOAL PROTEIN; PROTOZOAL VACCINE; RECOMBINANT VACCINE;

DRUG DELIVERY SYSTEM; HUMAN; IMMUNE RESPONSE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VISCERAL LEISHMANIASIS; ANIMAL; DOG; DOG DISEASES; IMMUNOLOGY; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; NEGLECTED DISEASES;

NASO HEXACANTHUS;

ANIMALS; ANTIGENS, PROTOZOAN; DOG DISEASES; DOGS; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; NEGLECTED DISEASES; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; VACCINES, ATTENUATED; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 84930435025     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2015.03.017     Document Type: Review

References (101)

1. Abdian N., Gholami E., Zahedifard F., Safaee N., Rafati S. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis. Exp. Parasitol. 2011, 127:627.
2. Agallou M., Margaroni M., Karagouni E. Cellular vaccination with bone marrow-derived dendritic cells pulsed with a peptide of Leishmania infantum KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis. Vaccine 2011, 29(31):5053.
3. Agallou M., Smirlis D., Soteriadou K.P., Karagouni E. Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis. Vaccine 2012, 30(34):5086.
4. Ali N., Nakhasi H.L., Valenzuela J.G., Reis A.B. Targeted immunology for prevention and cure of VL. Front. Immunol. 2014, 5:660.
5. Alvar J., Croft S.L., Kaye P., Khamesipour A., Sundar S., Reed S.G. Case study for a vaccine against leishmaniasis. Vaccine 2013, 31(Suppl. 2):B244.
6. Araujo M.S., de Andrade R.A., Vianna L.R., Mayrink W., Reis A.B., Sathler-Avelar R., Teixeira-Carvalho A., Andrade M.C., Mello M.N., Martins-Filho O.A. Despite Leishvaccine and Leishmune trigger distinct immune profiles, their ability to activate phagocytes and CD8+ T-cells support their high-quality immunogenic potential against canine visceral leishmaniasis. Vaccine 2008, 26(18):2211.
7. Araújo M.S., de Andrade R.A., Sathler-Avelar R., Magalhães C.P., Carvalho A.T., Andrade M.C., Campolina S.S., Mello M.N., Vianna L.R., Mayrink W., Reis A.B., Malaquias L.C., Rocha L.M., Martins-Filho O.A. Immunological changes in canine peripheral blood leukocytes triggered by immunization with first or second generation vaccines against canine visceral leishmaniasis. Vet. Immunol. Immunopathol. 2011, 141:64.
8. Bagre A.P., Jain K., Jain N.K. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment. Int. J. Pharm. 2013, 456(1):31.
9. Basu R., Bhaumik S., Basu J.M., Naskar K., De T., Roy S. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J. Immunol. 2005, 174(11):7160.
10. Basu R., Roy S., Walden P. HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages. J. Infect. Dis. 2007, 195(9):1373.
11. Bongiorno G., Paparcone R., Foglia Manzillo V., Oliva G., Cuisinier A.M., Gradoni L. Vaccination with LiESP/QA-21 (CaniLeish®) reduces the intensity of infection in Phlebotomus perniciosus fed on Leishmania infantum infected dogs - a preliminary xenodiagnosis study. Vet. Parasitol. 2013, 197(3-4):691.
12. Borja-Cabrera G.P., Correia Pontes N.N., da Silva V.O., Paraguai de Souza E., Santos W.R., Gomes E.M., Luz K.G., Palatnik M., Palatnik de Sousa C.B. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN). Vaccine 2002, 20(27-28):3277.
13. Bourdoiseau G., Hugnet C., Gonçalves R.B., Vezilier F., Petit-Didier E., Papierok G., Lemesre J.L. Effective humoral and cellular immunoprotective responses in LiESAp-MDP vaccinated protected dogs. Vet. Immunol. Immunopathol. 2009, 128(1-3):71.
14. Breton M., Tremblay M.J., Ouellette M., Papadopoulou B. Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect. Immun. 2005, 73(10):6372.
15. Carson C., Antoniou M., Ruiz-Argüello M.B., Alcami A., Christodoulou V., Messaritakis I., Blackwell J.M., Courtenay O. A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis. Vaccine 2009, 27(7):1080.
16. Chakravarty J., Kumar S., Trivedi S., Rai V.K., Singh A., Ashman J.A., Laughlin E.M., Coler R.N., Kahn S.J., Beckmann A.M., Cowgill K.D., Reed S.G., Sundar S., Piazza F.M. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine 2011, 29(19):3531.
17. Choudhury R., Das P., De T., Chakraborti T. 115kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity. Immunobiology 2013, 218(1):114.
18. Chowdhury B.P., Bandyopadhyay S., Das S., Majumder S., Jha M.K., Majumdar S.B., Saha B., Majumdar S. The host-protective effect of arabinosylated lipoarabinomannan against Leishmania donovani infection is associated with restoration of IFN-γ responsiveness. PLoS One 2015, 10(2):e0117247.
19. Da Silva V.O., Borja-Cabrera G.P., Correia Pontes N.N., de Souza E.P., Luz K.G., Palatnik M., Palatnik de Sousa C.B. A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN). Vaccine 2000, 19(9-10):1082.
20. da Silva R.A., Tavares N.M., Costa D., Pitombo M., Barbosa L., Fukutani K., Miranda J.C., de Oliveira C.I., Valenzuela J.G., Barral A., Soto M., Barral-Netto M., Brodskyn C. DNA vaccination with KMP11 and Lutzomyia longipalpis salivary protein protects hamsters against visceral leishmaniasis. Acta Trop. 2011, 120(3):185.
21. Daneshvar H., Coombs G.H., Hagan P., Phillips R.S. Leishmania mexicana and Leishmania major: attenuation of wild-type parasites and vaccination with the attenuated lines. J. Infect. Dis. 2003, 187(10):1662.
22. Daneshvar H., Namazi M.J., Kamiabi H., Burchmore R., Cleaveland S., Phillips S. Gentamicin-attenuated Leishmania infantum vaccine: protection of dogs against canine visceral leishmaniosis in endemic area of southeast of Iran. PLoS Negl. Trop. Dis. 2014, 8(4):e2757.
23. Datta S., Adak R., Chakraborty P., Haldar A.K., Bhattacharjee S., Chakraborty A., Roy S., Manna M. Radio-attenuated leishmanial parasites as immunoprophylactic agent against experimental murine visceral leishmaniasis. Exp. Parasitol. 2012, 130(1):39.
24. Datta S., Roy S., Manna M. Therapy with radio-attenuated vaccine in experimental murine visceral leishmaniasis showed enhanced T cell and inducible nitric; oxide synthase levels, suppressed tumor growth factor-beta production with higher expression of some signaling molecules. Braz. J. Infect. Dis. 2015, 19(1):36.
25. De Oliveira C.I., Nascimento I.P., Barral A., Soto M., Barral-Netto M. Challenges and perspectives in vaccination against leishmaniasis. Parasitol. Int. 2009, 58(4):319.
26. DebRoy S., Keenan A.B., Ueno N., Jeronimo S.M., Donelson J.E., Wilson M.E. Leishmania infantum chagasi: a genome-based approach to identification of excreted/secreted proteins. Exp. Parasitol. 2010, 126(4):582.
27. Dey R., Dagur P.K., Selvapandiyan A., McCoy J.P., Salotra P., Duncan R., Nakhasi H.L. Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice. J. Immunol. 2013, 190(5):2138.
28. Elfaki M.E., Khalil E.A., De Groot A.S., Musa A.M., Gutierrez A., Younis B.M., Salih K.A., El-Hassan A.M. Immunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccines. Hum. Vaccine Immunother. 2012, 8(12):1769.
29. Faleiro R.J., Kumar R., Hafner L.M., Engwerda C.R. Immune regulation during chronic visceral leishmaniasis. PLoS Negl. Trop. Dis. 2014, 8(7):e2914.
30. Fernandes A.P., Coelho E.A., Machado-Coelho G.L., Grimaldi G., Gazzinelli R.T. Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives. Curr. Opin. Microbiol. 2012, 15(4):476.
31. Fernandes C.B., Junior J.T., de Jesus C., Souza B.M., Larangeira D.F., Fraga D.B., Tavares Veras P.S., Barrouin-Melo S.M. Comparison of two commercial vaccines against visceral leishmaniasis in dogs from endemic areas: IgG, and subclasses, parasitism, and parasite transmission by xenodiagnosis. Vaccine 2014, 32(11):1287.
32. Ferreira J.H., Gentil L.G., Dias S.S., Fedeli C.E., Katz S., Barbiéri C.L. Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis. Vaccine 2008, 26(5):677.
33. Gamboa-Leon R., Paraguai de Souza E., Borja-Cabrera G.P., Santos F.N., Myashiro L.M., Pinheiro R.O., Dumonteil E., Palatnik-de-Sousa C.B. Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani. Vaccine 2006, 24(22):4863.
34. Gomes R., Teixeira C., Teixeira M.J., Oliveira F., Menezes M.J., Silva C., de Oliveira C.I., Miranda J.C., Elnaiem D.E., Kamhawi S., Valenzuela J.G., Brodskyn C.I. Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(22):7845.
35. Goto Y., Bogatzki L.Y., Bertholet S., Coler R.N., Reed S.G. Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant. Vaccine 2007, 25(42):7450.
36. Gour J.K., Kumar V., Singh N., Bajpai S., Pandey H.P., Singh R.K. Identification of Th1-responsive leishmanial excretory-secretory antigens (LESAs). Exp. Parasitol. 2012, 132(3):355.
37. Gradoni L. Canine Leishmania vaccines: still a long way to go. Vet. Parasitol. 2015, 10.1016/j.vetpar.2015.01.003.
38. Guha R., Das S., Ghosh J., Naskar K., Mandala A., Sundar S., Dujardin J.C., Roy S. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani. Vaccine 2013, 31(15):1905.
39. Gupta R., Kushawaha P.K., Tripathi C.D., Sundar S., Dube A. A novel recombinant Leishmania donovani p45, a partial coding region of methionine aminopeptidase, generates protective immunity by inducing a Th1 stimulatory response against experimental visceral leishmaniasis. Int. J. Parasitol. 2012, 42(5):429.
40. Islamuddin M., Chouhan G., Farooque A., Dwarakanath B.S., Sahal D., Afrin F. Th1-biased immunomodulation and therapeutic potential of Artemisia annua in murine visceral leishmaniasis. PLoS Negl. Trop. Dis. 2015, 9(1):e3321.
41. Jain K., Jain N.K. Novel therapeutic strategies for treatment of visceral leishmaniasis. Drug Discov. Today 2013, 18(23-24):1272.
42. Jain K., Kesharwani P., Gupta U., Jain N.K. A review of glycosylated carriers for drug delivery. Biomaterials 2012, 33(16):4166.
43. Jain A., Jain K., Kesharwani P., Jain N.K. Low density lipoproteins mediated nanoplatforms for cancer targeting. J. Nanopart. Res. 2013, 15:1888.
44. Jain K., Mehra N.K., Jain N.K. Potentials and emerging trends in nanopharmacology. Curr. Opin. Pharmacol. 2014, 15C:97.
45. Jain K., Verma A.K., Mishra P.R., Jain N.K. Characterization and evaluation of amphotericin B loaded MDP conjugated poly(propylene imine) dendrimers. Nanomedicine 2015, 10.1016/j.nano.2014.11.008.
46. Jain K., Verma A.K., Mishra P.R., Jain N.K. Surface engineered dendrimeric nanoconjugates for macrophage targeted delivery of amphotericin B: formulation development, in vitro and in vivo evaluation. Antimicrob. Agents Chemother. 2015, 10.1128/AAC.04213-14.
47. Jamshidi Sh., Avizeh R., Mohebali M., Bokaie S. Immunotherapy using autoclaved L. major antigens and M. vaccae with Meglumine antimoniate, for the treatment of experimental canine visceral leishmaniasis. Iran. J. Parasitol. 2011, 6(3):26.
48. John T.J., Dandona L., Sharma V.P., Kakkar M. Continuing challenge of infectious diseases in India. Lancet 2011, 377(9761):252.
49. Joshi S., Rawat K., Yadav N.K., Kumar V., Siddiqi M.I., Dube A. Visceral leishmaniasis: advancements in vaccine development via classical and molecular approaches. Front. Immunol. 2014, 5:380.
50. Kamil A.A., Khalil E.A., Musa A.M., Modabber F., Mukhtar M.M., Ibrahim M.E., Zijlstra E.E., Sacks D., Smith P.G., Zicker F., El-Hassan A.M. Alum-precipitated autoclaved Leishmania major plus Bacille Calmette-Guérrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers. Trans. R. Soc. Trop. Med. Hyg. 2003, 97(3):365.
51. Kaur T., Thakur A., Kaur S. Protective immunity using MPL-A and autoclaved Leishmania donovani as adjuvants along with a cocktail vaccine in murine model of visceral leishmaniasis. J. Parasit. Dis. 2013, 37(2):231.
52. Kaur H., Thakur A., Kaur S. Studies on cocktails of 31kDa, 36kDa and 51kDa antigens of Leishmania donovani along with saponin against murine visceral leishmaniasis. Parasite Immunol. 2015, 10.1111/pim.12176.
53. Kaye P.M., Aebischer T. Visceral leishmaniasis: immunology and prospects for a vaccine. Clin. Microbiol. Infect. 2011, 17(10):1462.
54. Kesharwani P., Jain K., Jain N.K. Dendrimer as nanocarrier for drug delivery. Prog. Polym. Sci. 2014, 39(2):268.
55. Khalil E.A., El Hassan A.M., Zijlstra E.E., Mukhtar M.M., Ghalib H.W., Musa B., Ibrahim M.E., Kamil A.A., Elsheikh M., Babiker A., Modabber F. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 2000, 356(9241):1565.
56. Khalil E.A., Musa A.M., Modabber F., El-Hassan A.M. Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (alum-precipitated autoclaved Leishmania major+BCG) in children: an extended phase II study. Ann. Trop. Paediatr. 2006, 26(4):357.
57. Khoshgoo N., Zahedifard F., Azizi H., Taslimi Y., Alonso M.J., Rafati S. Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals. Vaccine 2008, 26(46):5822.
58. Kumar A., Misra P., Sisodia B., Shasany A.K., Sundar S., Dube A. Proteomic analyses of membrane enriched proteins of Leishmania donovani Indian clinical isolate by mass spectrometry. Parasitol. Int. 2015, 10.1016/j.parint.2015.01.004.
59. Kumari S., Samant M., Khare P., Misra P., Dutta S., Kolli B.K., Sharma S., Chang K.P., Dube A. Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis. Eur. J. Immunol. 2009, 39(1):178.
60. Kushawaha P.K., Gupta R., Sundar S., Sahasrabuddhe A.A., Dube A. Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge. J. Immunol. 2011, 187(12):6417.
61. Kushawaha P.K., Gupta R., Tripathi C.D., Sundar S., Dube A. Evaluation of leishmania donovani protein disulfide isomerase as a potential immunogenic protein/vaccine candidate against visceral leishmaniasis. PLoS One 2012, 7(4):e35670.
62. Lee B.Y., Bacon K.M., Shah M., Kitchen S.B., Connor D.L., Slayton R.B. The economic value of a visceral leishmaniasis vaccine in Bihar state, India. Am. J. Trop. Med. Hyg. 2012, 86(3):417.
63. Lemesre J.L., Holzmuller P., Gonçalves R.B., Bourdoiseau G., Hugnet C., Cavaleyra M., Papierok G. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Vaccine 2007, 25(21):4223.
64. Martin V., Vouldoukis I., Moreno J., McGahie D., Gueguen S., Cuisinier A.M. The protective immune response produced in dogs after primary vaccination with the LiESP/QA-21 vaccine (CaniLeish®) remains effective against an experimental challenge one year later. Vet. Res. 2014, 45:69.
65. Martin-Martin I., Molina R., Jiménez M. Identifying salivary antigens of Phlebotomus argentipes by a 2DE approach. Acta Trop. 2013, 126:229.
66. Martins V.T., Chávez-Fumagalli M.A., Costa L.E., Canavaci A.M., Lage P.S., Lage D.P., Duarte M.C., Valadares D.G., Magalhães R.D., Ribeiro T.G., Nagem R.A., Darocha W.D., Régis W.C., Soto M., Coelho E.A., Fernandes A.P., Tavares C.A. Antigenicity and protective efficacy of a Leishmania amastigote-specific protein, member of the super-oxygenase family, against visceral leishmaniasis. PLoS Negl. Trop. Dis. 2013, 7(4):e2148.
67. Masih S., Arora S.K., Vasishta R.K. Efficacy of Leishmania donovani ribosomal P1 gene as DNA vaccine in experimental visceral leishmaniasis. Exp. Parasitol. 2011, 129:55.
68. Matlashewski G., Arana B., Kroeger A., Battacharya S., Sundar S., Das P., Sinha P.K., Rijal S., Mondal D., Zilberstein D., Alvar J. Visceral leishmaniasis: elimination with existing interventions. Lancet Infect. Dis. 2011, 11(4):322.
69. Mehra N.K., Jain K., Jain N.K. Pharmaceutical and biomedical applications of surface engineered carbon nanotubes. Drug Discov. Today 2015, 10.1016/j.drudis.2015.01.006.
70. Mohebali M., Khamesipour A., Mobedi I., Zarei Z., Hashemi-Fesharki R. Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran. Vaccine 2004, 22(29-30):4097.
71. Moreno J., Vouldoukis I., Schreiber P., Martin V., McGahie D., Gueguen S., Cuisinier A.M. Primary vaccination with the LiESP/QA-21 vaccine (CaniLeish) produces a cell-mediated immune response which is still present 1year later. Vet. Immunol. Immunopathol. 2014, 158(3-4):199.
72. Mukherjee A.K., Gupta G., Adhikari A., Majumder S., Kar Mahapatra S., Bhattacharyya Majumdar S., Majumdar S. Miltefosine triggers a strong proinflammatory cytokine response during visceral leishmaniasis: role of TLR4 and TLR9. Int. Immunopharmacol. 2012, 12(4):565.
73. Musa A.M., Khalil E.A., Mahgoub F.A., Elgawi S.H., Modabber F., Elkadaru A.E., Aboud M.H., Noazin S., Ghalib H.W., El-Hassan A.M. Leishmaniasis Research Group/Sudan. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Trans. R. Soc. Trop. Med. Hyg. 2008, 102(1):58.
74. Nagill R., Kaur S. Vaccine candidates for leishmaniasis: a review. Int. Immunopharmacol. 2011, 11:1464.
75. Nagill R., Mahajan R., Sharma M., Kaur S. Induction of cellular and humoral responses by autoclaved and heat-killed antigen of Leishmania donovani in experimental visceral leishmaniasis. Parasitol. Int. 2009, 58(4):359.
76. Nico D., Borges R.M., Brandão L.M., Feijó D.F., Gomes D.C., Palatnik M., Rodrigues M.M., da Silva A.J., Palatnik-de-Sousa C.B. The adjuvanticity of Chiococca alba saponins increases with the length and hydrophilicity of their sugar chains. Vaccine 2012, 30(21):3169.
77. Oliveira-Freitas E., Casas C.P., Borja-Cabrera G.P., Santos F.N., Nico D., Souza L.O., Tinoco L.W., da Silva B.P., Palatnik M., Parente J.P., Palatnik-de-Sousa C.B. Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis. Vaccine 2006, 24(18):3909.
78. Papadopoulou B., Roy G., Breton M., Kundig C., Dumas C., Fillion I., Singh A.K., Olivier M., Ouellette M. Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination. Infect. Immun. 2002, 70(1):62.
79. Paraguai de Souza E., Bernardo R.R., Palatnik M., Palatnik de Sousa C.B. Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani. Vaccine 2001, 19(23-24):3104.
80. Pereira L., Abbehusen M., Teixeira C., Cunha J., Nascimento I.P., Fukutani K., Dos-Santos W., Barral A., de Oliveira C.I., Barral-Netto M., Soto M., Brodskyn C.I. Vaccination with Leishmania infantum acidic ribosomal P0 but not with nucleosomal histones proteins controls Leishmania infantum infection in hamsters. PLoS Negl. Trop. Dis. 2015, 10(2):e0003490.
81. Ponte C.B., Alves E.A., Sampaio R.N., Urdapilleta A.A., Kückelhaus Cdos S., Muniz-Junqueira M.I., Kückelhaus S.A. Miltefosine enhances phagocytosis but decreases nitric oxide production by peritoneal macrophages of C57BL/6 mice. Int. Immunopharmacol. 2012, 13:114.
82. Rafati S., Zahedifard F., Nazgouee F. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 2006, 24(12):2169.
83. Ramos I., Alonso A., Marcen J.M., Peris A., Castillo J.A., Colmenares M., Larraga V. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response. Vaccine 2008, 26(3):333.
84. Ravindran R., Maji M., Ali N. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route. Mol. Pharm. 2012, 9(1):59.
85. Resende L.A., Roatt B.M., Aguiar-Soares R.D., Viana K.F., Mendonça L.Z., Lanna M.F., Silveira-Lemos D., Corrêa-Oliveira R., Martins-Filho O.A., Fujiwara R.T., Carneiro C.M., Reis A.B., Giunchetti R.C. Cytokine and nitric oxide patterns in dogs immunized with LBSap vaccine, before and after experimental challenge with Leishmania chagasi plus saliva of Lutzomyia longipalpis. Vet. Parasitol. 2013, 198(3-4):371.
86. Roatt B.M., Aguiar-Soares R.D., Coura-Vital W., Ker H.G., Moreira Nd, Vitoriano-Souza J., Giunchetti R.C., Carneiro C.M., Reis A.B. Immunotherapy and immunochemotherapy in visceral leishmaniasis: promising treatments for this neglected disease. Front. Immunol. 2014, 5:272.
87. Saha P., Mudhopadhyay D., Chatterjee M. Immunomodulation by chemotherapeutic agents against Leishmaniasis. Int. Immunopharmacol. 2011, 11:1668.
88. Saljoughian N., Zahedifard F., Doroud D., Doustdari F., Vasei M., Papadopoulou B., Rafati S. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice. Parasite Immunol. 2013, 35(12):397.
89. Saljoughian N., Taheri T., Zahedifard F., Taslimi Y., Doustdari F., Bolhassani A., Doroud D., Azizi H., Heidari K., Vasei M., Namvar Asl N., Papadopoulou B., Rafati S. Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis. PLoS Negl. Trop. Dis. 2013, 7(4):e2174.
90. Santos D.M., Carneiro M.W., de Moura T.R., Fukutani K., Clarencio J., Soto M., Espuelas S., Brodskyn C., Barral A., Barral-Netto M., de Oliveira C.I. Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11. Int. J. Nanomedicine 2012, 7:2115.
91. Satti I.N., Osman H.Y., Daifalla N.S., Younis S.A., Khalil E.A., Zijlstra E.E., El Hassan A.M., Ghalib H.W. Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers. Vaccine 2001, 19(15-16):2100.
92. Silvestre R., Cordeiro-Da-Silva A., Santarem N., Vergnes B., Sereno D., Ouaissi A. SIR2-deficient Leishmania infantum induces a defined IFN-gamma/IL-10 pattern that correlates with protection. J. Immunol. 2007, 179(5):3161.
93. Singh B., Sundar S. Leishmaniasis: vaccine candidates and perspectives. Vaccine 2012, 30:3834.
94. Singh O.P., Stober C.B., Singh A.K., Blackwell J.M., Sundar S. Cytokine responses to novel antigens in an Indian population living in an area endemic for visceral leishmaniasis. PLoS Negl. Trop. Dis. 2012, 6(10):e1874.
95. Sinha S., Kumar A., Sundaram S. A comprehensive analysis of LACK (Leishmania homologue of receptors for activated C kinase) in the context of visceral leishmaniasis. Bioinformation 2013, 9(16):832.
96. Stockdale L., Newton R. A review of preventative methods against human leishmaniasis infection. PLoS Negl. Trop. Dis. 2013, 7(6):e2278.
97. Sukumaran B., Tewary P., Saxena S., Madhubala R. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani. Vaccine 2003, 21(11-12):1292.
98. Trigo J., Abbehusen M., Netto E.M., Nakatani M., Pedral-Sampaio G., de Jesus R.S., Goto Y., Guderian J., Howard R.F., Reed S.G. Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE. Vaccine 2010, 28(19):3333.
99. Van Griensven J., Diro E. Visceral leishmaniasis. Infect. Dis. Clin. North Am. 2012, 26:309.
100. Vitoriano-Souza J., Moreira Nd, Menezes-Souza D., Roatt B.M., de Oliveira Aguiar-Soares R.D., Siqueira-Mathias F.A., de Oliveira Cardoso J.M., Giunchetti R.C., de Sá R.G., Corrêa-Oliveira R., Carneiro C.M., Reis A.B. Dogs immunized with LBSap vaccine displayed high levels of IL-12 and IL-10 cytokines and CCL4, CCL5 and CXCL8 chemokines in the dermis. Mol. Immunol. 2013, 56(4):540.
101. Yam K.K., Hugentobler F., Pouliot P., Stern A.M., Lalande J.D., Matlashewski G., Olivier M., Cousineau B. Generation and evaluation of A2-expressing Lactococcus lactis live vaccines against Leishmania donovani in BALB/c mice. J. Med. Microbiol. 2011, 60(Pt 9):1248.